Rodriguez Benigno, Bobak David A
Division of Infectious Diseases, University Hospitals of Cleveland, 2061 Cornell Road, Suite 401, Cleveland, OH 44106, USA.
Curr Infect Dis Rep. 2005 Mar;7(2):91-102. doi: 10.1007/s11908-005-0067-0.
As the survival of HIV-infected patients has been lengthening over the past 10 years as a consequence of effective antiretroviral therapy, hepatitis C virus (HCV) coinfection has emerged as a major cause of morbidity and mortality in this population. HCV/HIV coinfection is associated with accelerated progression of liver disease, untoward effects on the immunologic and virologic response to antiretroviral medications, and possibly with a more aggressive course of HIV disease. The results of major trials of combination therapy for HCV in coinfected patients have clearly established the combination of pegylated interferon-alpha with ribavirin as the treatment of choice in this population. However, the effectiveness and tolerability of this regimen remains suboptimal, particularly in patients with genotype 1 HCV infection. This paper reviews the impact of HCV coinfection in HIV-infected patients, outlines current concepts on management and antiviral treatment, and discusses some of the newer agents, currently in the therapeutic pipeline, that are directed against novel molecular targets.
在过去十年中，由于有效的抗逆转录病毒疗法，HIV感染患者的生存期得以延长，丙型肝炎病毒（HCV）合并感染已成为该人群发病和死亡的主要原因。HCV/HIV合并感染与肝病进展加速、对抗逆转录病毒药物的免疫和病毒学反应产生不良影响以及可能更具侵袭性的HIV病程有关。针对合并感染患者的HCV联合治疗主要试验结果已明确确定聚乙二醇化α干扰素与利巴韦林联合用药是该人群的首选治疗方法。然而，该方案的有效性和耐受性仍然欠佳，尤其是在基因型1 HCV感染患者中。本文综述了HCV合并感染对HIV感染患者的影响，概述了当前管理和抗病毒治疗的概念，并讨论了一些正在研发的、针对新型分子靶点的新型药物。
